<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:374473051;
mso-list-template-ids:2109085544;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:716972023;
mso-list-template-ids:22306846;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2
{mso-list-id:944727687;
mso-list-template-ids:692213516;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3
{mso-list-id:1191917673;
mso-list-template-ids:-1652511726;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4
{mso-list-id:1790971184;
mso-list-template-ids:1568169474;}
@list l4:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l4:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l4:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l4:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5
{mso-list-id:1879009422;
mso-list-template-ids:-1343691728;}
@list l5:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l5:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l5:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l5:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.countyhealthrankings.org/research-grants">County Health Rankings and Roadmaps Research Grants: Building a Culture of Health County by County</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These Research Grants will support scholarly inquiry from outside the program to identify potential improvements to County Health Rankings and Roadmaps (CHR&R) tools to increase their
strategic use and the impact of efforts to improve health and increase health equity. The Call for Proposals includes four specific focus areas, informed by Public Health Critical Race Praxis: <o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l4 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Contemporary patterns of racial relations and spatial inequities using the CHR&R data and tools <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Knowledge production that supports understanding of the context of racial inequity and systemic racism for inclusion in CHR&R <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Conceptualization and measurement of spatial and racial differences that evolve CHR&R data sources, methods, tools, and narratives <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l4 level1 lfo3"><span style="font-size:12.0pt;font-family:Palatino">Actions to counter racial, spatial, and power inequities to strengthen the potential for CHR&R to contribute to change <o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Up to $600,000 will be available for research under this CFP, with a combination of: <o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l5 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Targeted studies – up to $50,000 for a maximum of 12 months. <o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l5 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Complex/comprehensive studies – up to $100,000 for a maximum of 12 months. Applicants seeking higher funding amounts will need to clearly specify the data
collection or analysis steps requiring the higher amount. <o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Brief proposals due June 4, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: April 24.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://vilcek.org/prizes/vilcek-prizes-for-creative-promise/" target="_blank">Vilcek Prizes For Creative Promise in Biomedical Science</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Three unrestricted cash prizes of $50,000 each will be awarded to young foreign-born biomedical scientists who demonstrate outstanding early achievement in basic, applied, and/or translational
biomedical science. Applicants must have earned a doctoral degree (MD, PhD, or equivalent) and should hold full-time positions at an academic institution or other organization, including positions of assistant or associate professor, or equivalent independent
position.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">To be eligible, applicants must have been born outside the United States; be no older than age 38 as of December 31, 2021 (born on or after January 1, 1983); a naturalized citizen or permanent
resident (green card holder) of the United States; and hold an H1B or O-1 visa and have been living and working in the United States for at least five years, or have been granted Deferred Action for Childhood Arrivals (DACA) relief.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 11, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Trans-Atlantic Platform Recovery, Renewal and Resilience in a Post-Pandemic World (RRR) Call for Proposals<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://transatlanticplatform.com/t-ap-recovery-renewal-and-resilience-in-a-post-pandemic-world-rrr/">Overview</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://transatlanticplatform.com/wp-content/uploads/2021/04/RRR-Call-for-Proposals-English.pdf">Call for Proposals</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">See also
<a href="https://www.nsf.gov/pubs/2021/nsf21074/nsf21074.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click">
NSF Dear Colleague Letter</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This RRR call emphasizes the following five main challenges related to COVID-19: (i) reducing inequalities and vulnerabilities; (ii) building a more resilient, inclusive and sustainable
society; (iii) fostering democratic governance and political participation; (iv) advancing responsible and inclusive digital innovation; and (v) ensuring effective and accurate communication and media. A focus on these five challenges will leverage the social
science and humanities research to understand and address the complex societal effects of COVID-19 pandemic, and inform mitigation efforts, thus contributing to a more equitable, resilient and sustainable future. Key to the approach is the added value of new
perspectives and insights generated by transnational and interdisciplinary collaborations. Projects should be of 2-3 years in length; funding depends on the countries of origin of the investigators involved in the project.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Required intention to submit form due June 14, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.rwjf.org/en/library/funding-opportunities/2021/health-equity-scholars-for-action.html?rid=0034400001rm2ZLAAY&et_cid=2456344">Robert Wood Johnson Foundation: Health
Equity Scholars for Action</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The goal of the Health Equity Scholars for Action (HES4A) competition is to support the career development and academic advancement of
<b>researchers from historically underrepresented backgrounds who conduct health equity research</b>. Grants will be awarded to address the challenges that underrepresented researchers experience; help them overcome obstacles to earning tenure; and make progress
toward acquiring independent research funding. Grants will support three aspects of career development: research, mentorship, and connection with a community of support. Eligibility criteria include: applicant must have completed a doctoral degree within the
last five years and must be from a historically underrepresented group. Grants of $250,000 each will be awarded through this program. Funds will cover up to 70 percent of the scholar’s salary for two years (capped at $75,000 per year), with the remainder of
the award to be used for research and other related expenses. Up to 15 grants will be awarded. Grants will be for 24 months in duration.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of intent due June 16, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">NICHD Small Research Grant Programs (R03 Clinical Trial Required and Basic Experimental Studies with Humans Required)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-221.html">R03 Clinical Trial Required</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects
that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development
of research methodology; and development of new research technology.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PA-21-231.html">R03 Basic Experimental Studies with Humans Required</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This funding opportunity announcement is for basic science experimental studies involving humans, referred to in
<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-212.html">NOT-OD-18-212</a> as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition
of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans
for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires May 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for June 16, 2021 standard date: June 3.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://michelsonprizes.smapply.org/">Michelson Next Generation Grants: Human Vaccines Project</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Michelson Prizes: Next Generation Grants are $150,000 research grants given annually to support promising researchers who are applying disruptive concepts and inventive processes to
advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. The 2021 Michelson Prizes will be looking for research proposals in two areas:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo9"><b><span style="font-size:12.0pt;font-family:Palatino">Human Immunology and Vaccine Research</span></b><span style="font-size:12.0pt;font-family:Palatino">: The committee will be looking for research aimed
at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo9"><b><span style="font-size:12.0pt;font-family:Palatino">Climate Change and Human Immunology</span></b><span style="font-size:12.0pt;font-family:Palatino">: Climate change has a profound effect on human health;
pollution and other environmental stressors related to climate change increase susceptibility to disease, especially in vulnerable populations. Harnessing the immune system will be critical to mitigate negative health impacts. The committee is looking for
research that expands our understanding of the potential effects of climate change on immune function with a particular interest in research that will directly translate into vaccine and immunotherapy development to mitigate its impact.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due June 18, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 7.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.damonrunyon.org/for-scientists/application-guidelines/innovation" target="_blank">Damon Runyon Cancer Research Foundation Rachleff Innovation Award</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential
to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain
traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. The
<b>Stage 1 award will be for two years</b>, $200,000 per year ($400,000 total) with the opportunity for up to two additional years of funding (up to four years total for $800,000). No IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Stage 1 application due July 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: June 21.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://thehopefoundation.org/research-funding/juried-programs/swog-early-exploration-development-seed-fund/">Hope Foundation for Cancer Research: SWOG Early Exploration and Development
(SEED) Fund</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational
medicine studies) within SWOG and the National Clinical Trials Network (NCTN).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility
studies (including early-stage clinical trials), small, self-contained research projects, or development of research methodology/technology.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Direct application to future SWOG research, larger in scope, is critical and will be a metric of success for this funding program. Another metric of success will be the ability to obtain
extramural funding based on studies done during the tenure of the support of this grant.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due July 1, 2021 and December 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for July 1, 2021 due date: June 21.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/bmfrp" target="_blank">Bone Marrow Failure Research Program</a><br>
<b>Idea Development Award</b><br>
Pre-application: July 9, 2021. Invited full application: October 12, 2021.<br>
<b>Investigator Initiated Research Award</b><br>
Pre-application: July 9, 2021. Invited full application: October 12, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: June 28.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/bcrp" target="_blank">Breast Cancer Research Program</a><br>
<b>Breakthrough Award Levels 1 and 2</b><br>
Pre-application (required letter of intent): August 31, 2021. Full application: September 14, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: August 31 (due to Labor Day holiday).</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Breakthrough Award Level</b> 3<br>
Pre-application: June 24, 2021. Invited full application: October 5, 2021.<br>
<b>Breakthrough Award Level 4</b><br>
Pre-application: June 24, 2021. Invited full application: October 5, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: June 14.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Era of Hope Scholar Award</b><br>
Pre-application (required letter of intent): August 31, 2021. Full application: September 14, 2021. Confidential letters of recommendation: September 17, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: August 31 (due to Labor Day holiday).</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/kcrp" target="_blank">Kidney Cancer Research Program</a><br>
<b>Concept Award</b><br>
Pre-application (required letter of intent): June 22, 2021. Full application: July 13, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: June 29 (due to July 4 holiday).</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Idea Development Award</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
Pre-application: June 15, 2021. Invited full application: October 5, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: June 2.</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
<b>Postdoctoral and Clinical Fellowship Award</b><br>
Pre-application (required letter of intent): June 22, 2021. Full application: July 13, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: June 29 (due to July 4 holiday).</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Translational Research Fellowship Award</span></b><span style="font-size:12.0pt;font-family:Palatino"><br>
Pre-application: June 15, 2021. Invited full application: October 5, 2021.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for pre-application: June 2.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://cdmrp.army.mil/funding/lrp" target="_blank">Lupus Research Program</a><br>
<b>Idea Award</b><br>
Pre-application (required letter of intent): August 24. Full application: September 22.<br>
<b>Impact Award</b><br>
Pre-application (required letter of intent): August 24. Full application: September 22.<br>
<b>Transformative Vision Award</b><br>
Pre-application (required letter of intent): August 24. Full application: September 22.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for full application: September 9.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.nsf.gov/pubs/2021/nsf21069/nsf21069.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click">NSF Dear Colleague Letter: Models for Uncovering Rules and Unexpected Phenomena in Biological
Systems (MODULUS)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The National Science Foundation (NSF) Division of Mathematical Sciences (DMS), in collaboration with the Division of Molecular and Cellular Biosciences (MCB), seeks to promote interdisciplinary
research that enables novel mathematical and computational approaches that capture and explore the full range of mechanisms and biological variability needed to better understand complex and nonlinear behavior across multiple biological systems and scales.
The development of replicative or descriptive models for complex biological systems remains a challenging task, yet models that move beyond replication into the realm of prediction and ultimately becoming indispensable tools for discovery-driven biology are
severely lacking. A paradigm shift in the current approach to interdisciplinary mathematical biology is needed to promote the realization of modeling platforms that facilitate discovery of novel biological phenomena, rules, and theories. As part of the effort,
funding opportunities are available in fiscal years FY2021 and FY2022 to provide support for proposals from interdisciplinary teams comprised of mathematical, computational, and biological scientists to develop
<b><i>MOD</i></b><i>els for Uncovering Rules and Unexpected Phenomena in Biological Systems
<b>(MODULUS)</b></i>. This Dear Colleague Letter (DCL) is to encourage researchers involved in the biosciences and the mathematical sciences to collaborate in a substantive manner in biological investigations using novel mechanistic mathematical models to guide
biological exploration and discovery of new rules, phenomena, and theories in living systems. Proposals in response to this DCL should be submitted to either DMS via the
<a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5690">Mathematical Biology Program</a> or the MCB solicitation,
<a href="https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf21509">NSF 21-509</a>, directed to the Systems and Synthetic Biology program (8011). The proposal title should be prefaced with “MODULUS:”. Neither Division puts limits on proposal budgets and
expects budgets to be appropriate for the scope of the project proposed. The MCB solicitation accepts proposals without deadline.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Proposals accepted anytime.
<span style="color:red">Med-RA deadline to receive draft documents: Ten days before submission to sponsor.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://beta.sam.gov/opp/dfe93a5637fc419a8ea392ee949f9c79/view">DARPA: Biological Technologies</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The mission of BTO is to foster, demonstrate, and transition breakthrough research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and
the physical sciences. BTO’s research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S.
capabilities and resilience. BTO’s programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the Department of Defense (DoD) and addresses national security
priorities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Abstracts (highly recommended) and proposals reviewed on a rolling basis.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Final deadline to submit abstracts / proposals: April 20, 2022.</span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red">DARPA proposals have complex administrative requirements. Please notify Med-RA at least two months ahead of anticipated submission deadline.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-018.html" target="_blank">NIH Director’s Early Independence Awards (DP5 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The
<a href="https://commonfund.nih.gov/earlyindependence">NIH Director’s Early Independence Award</a> supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical
training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full
diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations, are strongly encouraged to apply to this Funding Opportunity
Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational,
or clinical research. The NIH Director’s Early Independence Award is a component of the
<a href="https://commonfund.nih.gov/highrisk">High-Risk, High-Reward Research program</a> of the
<a href="https://commonfund.nih.gov/">NIH Common Fund</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due September 3, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: August 23.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-017.html">Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial
Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement is to support the identification of mechanisms behind heterogeneous responses in the population to influenza infection
and/or vaccination through development and application of computational tools.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due September 8, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: August 25 (due to Labor Day holiday).</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-175.html">BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific
Processes in the Brain (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this Brain Research through Advancing Innovative Neurotechnologies<sup>®</sup> (BRAIN) Initiative is to encourage research that will develop and validate novel
tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating
the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific
cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly
desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due October 8, 2021; October 7, 2022; and October 6, 2023.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for October 8, 2021 due date: September 27.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b>CoM’s
unofficial funding opportunities blog</b></a><b>.</b><o:p></o:p></span></p>
</div>
</body>
</html>